Domestic substitution continues to accelerate, how should pharmaceutical machinery companies embrace new opportunities?

In recent years, due to the impact of the epidemic, the processing and production of some overseas factories have been limited, and orders have gradually shifted to Chinese production.
This has not only brought more development opportunities to domestic pharmaceutical companies, but has also begun to accelerate the pace of domestic substitution of imports
.
Pharmaceutical machinery companies are embracing a new round of opportunities (Source: Pharmaceutical Network) For example, Chutian Technology stated in an institutional survey on July 19 that the company had already deployed import substitution in the high-end market of vaccine products three years ago.
Product performance and quality have been able to meet the needs of high-end customers, and thus entered the high-end vaccine industry supply chain, and compete with imported equipment on the same platform
.
At present, the company is highly optimistic about the market demand growth brought about by the related stock market of import substitution in the future
.
In addition, Tofflon also stated that in the future, it will focus on the development strategy of "systematization, internationalization, and digital intelligence" to provide global customers with forward-looking and competitive pharmaceutical equipment, food equipment, and cell therapy equipment.
The solution
.
On the whole, the domestic pharmaceutical equipment industry has ushered in a new round of development opportunities while accelerating import substitution
.
According to statistics, the sales of China's pharmaceutical machinery industry in 2020 will be 19.
7 billion yuan, a year-on-year increase of 14.
6%
.
Following this development trend, China's pharmaceutical equipment market is expected to reach US$4.
58 billion in 2025, with a compound growth rate of 8.
1%
.
It should be noted that although with the continuous improvement of the quality and technology of local enterprises, and the continuous increase in overseas market demand, the delivery capabilities of domestic manufacturers have been further reflected, and domestic substitution is also accelerating; but in terms of domestic substitution of imports, domestic In fact, there are still some bottlenecks in pharmaceutical equipment companies
.
For example, domestic companies are still inferior in some core components and key technical fields
.
It is understood that China's pharmaceutical equipment is mainly concentrated in the middle and low-end areas
.
In the high-end field, the high-end equipment used by pharmaceutical companies has been mainly imported products for a long time.
The small number of domestic high-end pharmaceutical machine companies and the few competitive products cannot meet the needs of pharmaceutical companies to stabilize production and increase production efficiency.

.
For example, in June of this year, a pharmaceutical company installed fluidized bed and other new equipment in the production workshop, but according to the staff, the new equipment is imported equipment purchased by the company for the purpose of promoting the production of high-end pharmaceutical preparations and continuously expanding production capacity.

.
In this context, the industry believes that what domestic pharmaceutical equipment companies must do is to continue to increase R&D investment to improve their own capabilities, appropriately expand production capacity, and seize the current opportunities in order to strive to accept more domestic and foreign orders
.
Among them, high-end equipment is the prerequisite and key to the development of the manufacturing industry.
Therefore, vigorously developing high-end pharmaceutical machinery equipment will be the only way to improve the level of China's pharmaceutical machinery manufacturing industry and narrow the gap with imported equipment
.
It is worth mentioning that, in fact, in the context of the continuous expansion of the domestic pharmaceutical equipment industry and the relatively complete product range, many pharmaceutical equipment companies have already begun to enter the high-end market, especially the giant companies with R&D and technological advantages.
"Gearing gears", through innovating while expanding production, to seize the huge market space for domestic substitution
.
Take Chutian Technology as an example.
In terms of innovation, it has recently released nearly 20 technological innovations and iterative upgrade products
.
It is reported that among these nearly 20 products, wave-type bioreactors, automatic microcarrier suspension culture bioreactors, basket-type bioreactors, disposable mixing and mixing systems and other front-end biopharmaceutical process equipment are all unveiled for the first time.

.
In addition, in terms of production expansion, in April this year, Chutian Technology bid for land through bidding, auction and listing, and obtained the real estate certificate issued by the Ningxiang Natural Resources Bureau.
The land will be used for the company's future capacity expansion.

.
The industry believes that, on the whole, the pharmaceutical equipment industry has ushered in a new round of growth
.
In the future, with the acceleration of domestic substitution, the continuous development of the pharmaceutical industry, and the increasing demand for high-end pharmaceutical equipment in the pharmaceutical industry, it is expected that the performance of the domestic pharmaceutical equipment industry will have more room for imagination, and related companies will follow suit.
Come more positive
.